NICE asked to develop guidance on new treatments for breast and lung cancer, Crohns disease, ulcerative colitis, obesity and rheumatoid arthritis.
Feb 8, 2007 - 5:33:46 AM
The National Institute for Health and Clinical Excellence (NICE) today welcomes the announcement of additional topics for its forward work programme. Topics including new treatments for breast and lung cancer, Crohns disease, ulcerative colitis, obesity and rheumatoid arthritis, have been referred to NICE by the Secretary of State for Health in line with the national priorities they have established for the NHS.
|NICE has also been asked to appraise adalimumab for moderate to severely active Crohn%u2019s disease.|
The following topics have been referred:
2 clinical guidelines on:
o Rheumatoid arthritis in adults
o Diarrhoea and vomiting in children
1 rapid clinical guideline on:
o Acutely ill patients in hospital
5 technologies for appraisal as part of NICEs rapid single technology appraisal (STA) programme on:
o Bevacizumab for non-small cell lung cancer
o Certolizumab pegol for rheumatoid arthritis
o Infliximab for ulcerative colitis
o Lapatinib for advanced or metastatic breast cancer
o Rimonabant for the treatment of obese and overweight patients
3 technologies for appraisal as part of NICEs multiple technology appraisal (MTA) programme on:
o Endovascular stents for abdominal aortic aneurysms
o Machine versus cold (static) storage of donated kidneys
o Spinal cord stimulation for chronic pain
In addition, NICE has also been asked to appraise adalimumab for moderate to severely active Crohns disease. It has not yet been confirmed whether this will be appraised as part of the Institutes MTA or STA programmes.
Commenting on the referrals, Andrew Dillon, NICE Chief Executive said: NICE welcomes the referral of todays topics, which address areas of significant concern for those working in the NHS, patients and carers. We are keen to begin developing guidance that will help to inform their decisions about treatment and healthcare in these areas as soon as possible and we will publish details of the timetables for these topics on our web site shortly.
All rights reserved by RxPG Medical Solutions Private Limited ( www.rxpgnews.com )